Manufacturer of Controlled Substances; Notice of Registration, 55588-55589 [E9-25887]

Download as PDF 55588 Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices Dated: October 16, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–25895 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 9, 2009, Aldrich Chemical Company Inc., DBA Isotec, 3858 Benner Road, Miamisburg, Ohio 45342–4304, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: erowe on DSK5CLS3C1PROD with NOTICES Drug Schedule Gamma Hydroxybutyric Acid (2010). Methaqualone (2565) ................... Ibogaine (7260) ............................ Tetrahydrocannabinols (7370) ..... 2,5-Dimethoxyamphetamine (7396). Psilocyn (7438) ............................. Normorphine (9313) ..................... Acetylmethadol (9601) ................. Alphacetylmethadol except levoalphacetylmethadol (9603). Normethadone (9635) .................. Norpipanone (9636) ..................... 3-Methylfentanyl (9813) ................ Amphetamine (1100) .................... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... 1-Phenylcyclohexylamine (7460) Phencyclidine (7471) .................... Phenylacetone (8501) .................. 1-Piperidinocyclohexanecarbonitrile (8603). Cocaine (9041) ............................. Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Ethylmorphine (9190) ................... Hydrocodone (9193) ..................... Isomethadone (9226) ................... Meperidine (9230) ........................ Meperidine intermediate-A (9232) Meperidine intermediate-B (9233) Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk, (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. VerDate Nov<24>2008 15:34 Oct 27, 2009 I I I I I I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II II Jkt 220001 Drug Schedule Oxymorphone (9652) ................... II The company plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug testing and analysis. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009. Dated: October 20, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–25893 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–M DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 10, 2009, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule Gamma Hydroxybutyric Acid (2010). Tetrahydrocannabinols (7370) ..... Dihydromorphine (9145) ............... Difenoxin (9168) ........................... Propiram (9649) ........................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Nabilone (7379) ............................ Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Ecgonine (9180) ........................... Hydrocodone (9193) ..................... PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 I I I I I II II II II II II II II II II II II Drug Meperidine (9230) ........................ Methadone (9250) ........................ Methadone intermediate (9254) ... Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ Schedule II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for sale to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a controlled substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than December 28, 2009. Dated: October 21, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–26002 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated June 15, 2009, and published in the Federal Register on June 23, 2009, (74 FR 29720), Noramco Inc., Division of Ortho-McNeil, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II. The company plans to bulk manufacture the above listed controlled substance for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C 823(a) and determined that the registration of Noramco, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at E:\FR\FM\28OCN1.SGM 28OCN1 55589 Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices this time. DEA has investigated Noramco, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: October 20, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–25892 Filed 10–27–09; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P Dated: October 16, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–25887 Filed 10–27–09; 8:45 am] By Notice dated June 22, 2009, and published in the Federal Register on June 26, 2009, (74 FR 30621), Wildlife Laboratories Inc., 1401 Duff Drive, Suite 400, Fort Collins, Colorado 80524, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Carfentanil (9743), a basic class of controlled substance listed in schedule II. The company will manufacture the above listed controlled substance for sale to veterinary pharmacies, zoos, and for other animal and wildlife applications. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Wildlife Laboratories Inc. to manufacture the listed basic class(es) of controlled substance(s) is consistent with the public interest at this time. DEA has investigated Wildlife Laboratories, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class(es) of controlled substance(s) listed. By Notice dated February 5, 2009 and published in the Federal Register on February 11, 2009, (74 FR 6921), Siegfried (USA), Inc., 33 Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration erowe on DSK5CLS3C1PROD with NOTICES Manufacturer of Controlled Substances; Notice of Registration By Notice dated July 1, 2009, and published in the Federal Register on July 13, 2009, (74 FR 33476), Organix Inc., 240 Salem Street, Woburn, Massachusetts 01801, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Marihuana (7360), a basic class of controlled substance listed in schedule I. The company plans to manufacture a synthetic cannabinol in bulk for sale to its customers for research purposes. No other activity for this drug code is authorized for this registration. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Organix Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Organix Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. VerDate Nov<24>2008 15:34 Oct 27, 2009 Jkt 220001 DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances Notice of Registration Dated: October 16, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–25886 Filed 10–27–09; 8:45 am] BILLING CODE 4410–09–P PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration Drug Dihydromorphine (9145) ............... Amphetamine (1100) .................... Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Glutethimide (2550) ...................... Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Oripavine (9330) ........................... Oxymorphone (9652) ................... Schedule I II II II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Siegfried (USA), Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Siegfried (USA), Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. E:\FR\FM\28OCN1.SGM 28OCN1

Agencies

[Federal Register Volume 74, Number 207 (Wednesday, October 28, 2009)]
[Notices]
[Pages 55588-55589]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-25887]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated June 15, 2009, and published in the Federal 
Register on June 23, 2009, (74 FR 29720), Noramco Inc., Division of 
Ortho-McNeil, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made 
application by letter to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of Noroxymorphone (9668), a basic 
class of controlled substance listed in schedule II.
    The company plans to bulk manufacture the above listed controlled 
substance for distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C 823(a) and determined that the registration of 
Noramco, Inc. to manufacture the listed basic class of controlled 
substance is consistent with the public interest at

[[Page 55589]]

this time. DEA has investigated Noramco, Inc. to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic class of controlled substance listed.

     Dated: October 16, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-25887 Filed 10-27-09; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.